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Molecular predictors of progression-free and overall survival in
patients with newly diagnosed glioblastoma: a prospective
translational study of the German Glioma Network
Abstract
PURPOSE: The prognostic value of genetic alterations characteristic of glioblastoma in patients treated
according to present standards of care is unclear. PATIENTS AND METHODS: Three hundred one
patients with glioblastoma were prospectively recruited between October 2004 and December 2006 at
the clinical centers of the German Glioma Network. Two hundred fifty-eight patients had radiotherapy,
199 patients had temozolomide, 189 had both, and seven had another chemotherapy as the initial
treatment. The tumors were investigated for TP53 mutation, p53 immunoreactivity, epidermal growth
factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A
homozygous deletion, allelic losses on chromosome arms 1p, 9p, 10q, and 19q, O(6)-methylguanine
methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutations.
RESULTS: Median progression-free (PFS) and overall survival (OS) were 6.8 and 12.5 months.
Multivariate analysis revealed younger age, higher performance score, MGMT promoter methylation,
and temozolomide radiochemotherapy as independent factors associated with longer OS. MGMT
promoter methylation was associated with longer PFS (relative risk [RR], 0.5; 95% CI, 0.38 to 0.68; P <
.001) and OS (RR, 0.39; 95% CI, 0.28 to 0.54; P < .001) in patients receiving temozolomide. IDH1
mutations were associated with prolonged PFS (RR, 0.42; 95% CI, 0.19 to 0.91; P = .028) and a trend
for prolonged OS (RR, 0.43; 95% CI, 0.15 to 1.19; P = .10). No other molecular factor was associated
with outcome. CONCLUSION: Molecular changes associated with gliomagenesis do not predict
response to therapy in glioblastoma patients managed according to current standards of care. MGMT
promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct
subgroups.
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Abstract 
 
PURPOSE: The prognostic value of genetic alterations characteristic of glioblastoma 
in patients treated according to present standards of care is unclear. 
PATIENTS AND METHODS: 301 glioblastoma patients were prospectively recruited 
between October 2004 and December 2006 at the clinical centers of the German 
Glioma Network. 258 patients had radiotherapy, 199 patients had temozolomide, 189 
had both, 7 had another chemotherapy as the initial treatment. The tumors were 
investigated for TP53 mutation, p53 immunoreactivity, epidermal growth factor 
receptor (EGFR), cyclin-dependent kinase (CDK) 4 or murine double minute (MDM) 2 
amplification, CDKN2A homozygous deletion, allelic losses on chromosome arms 1p, 
9p, 10q and 19q, O6-methylguanine methyltransferase (MGMT) promoter 
methylation, and isocitrate dehydrogenase (IDH)-1 mutations. 
RESULTS: Median progression-free (PFS) and overall survival (OS) were 6.8 and 
12.5 months. Multivariate analysis revealed younger age, higher performance score, 
MGMT promoter methylation and temozolomide radiochemotherapy as independent 
factors associated with longer OS. MGMT promoter methylation was associated with 
longer PFS (RR 0.5, 95% CI 0.38-0.68, p < 0.001) and OS (RR: 0.39, 95%CI 0.28-
0.54, p<0.001) in patients receiving temozolomide. IDH-1 mutations were associated 
with prolonged PFS (RR  0.42, 95% CI: 0.19 - 0.91, p= 0.028) and a trend for 
prolonged OS (RR 0.43, 95% CI 0.15 – 1.19, p = 0.10). No other molecular factor 
was associated with outcome. 
CONCLUSION: Molecular changes associated with gliomagenesis do not predict 
response to therapy in glioblastoma patients managed according to current 
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standards of care. MGMT promoter methylation and IDH-1 mutational status allow for 
stratification into prognostically distinct subgroups. 
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Introduction 
 
Numerous chromosomal, genetic and epigenetic aberrations occur at more than 
random frequency in gliomas (1). However, the clinical value of most glioma-
associated molecular aberrations in terms of their significance as diagnostic, 
prognostic or predictive molecular markers has remained unclear (2-5). To date, only 
two molecular aberrations have been demonstrated to be of clinical significance in 
prospective clinical trials. Allelic losses on chromosome arms 1p and 19q are 
associated with a favorable prognosis in patients with oligodendroglial and 
oligoastrocytic anaplastic gliomas treated with radiotherapy or radiotherapy plus 
chemotherapy (6-9). MGMT promoter hypermethylation is associated with prolonged 
progression-free and overall survival in glioblastoma patients treated with alkylating 
agents such as nitrosoureas or temozolomide (10-13). To systematically investigate 
the prognostic significance of molecular genetic markers in gliomas beyond known 
clinical prognostic factors, we determined a set of common glioma-associated 
aberrations in a prospective manner for each glioblastoma patient recruited into the 
German Glioma Network (GGN). 
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Patients and Methods 
 
Patients 
The patients were prospectively enrolled in the clinical centers of the GGN: Bonn, 
Dresden, Freiburg, Hamburg, LMU Munich and Tübingen. The GGN is a clinical 
research network sponsored by the German Cancer Aid (Deutsche Krebshilfe) which 
in addition to the above-mentioned clinical centers includes associated centers for 
central neuropathology review in Bonn, molecular neuropathology in Düsseldorf and 
Heidelberg, and biometry in Leipzig. The GGN aims at enrolling all adult patients with 
gliomas seen at these centers since October 2004. Fresh-frozen tissue and blood 
samples are obtained from all patients with microsurgical tumor resection and clinical 
follow-up information is collected on electronic case report forms (CRF) in regular 
intervals (www.gliomnetzwerk.de). All activities of the GGN have been approved by 
the review boards of the participating institutions. Recruitment is ongoing. The data 
presented here include consecutive patients included until December 2006. 
 
Central reference pathology 
Formalin-fixed, paraffin-embedded material of all 301 patients was submitted from 
the local (neuro)pathologists of the GGN centers for an independent 
histopathological review to the German Brain Tumor Reference Center in Bonn. Four 
µm sections were cut and conventional hematoxylin/eosin and silver impregnation 
(Gomori) stainings and  basic immunohistochemical reactions for protein expression 
including glial fibrillary acidic protein (GFAP; polyclonal rabbit antibody, Dako, 
Hamburg, 1: 500 dilution), p53 (monoclonal murine, clone DO7, Dako, 1:70 dilution, 
microwave pretreatment with citrate buffer pH 6.0) and Ki-67 (monoclonal murine, 
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clone Mib-1, Dako, 1:50 dilution, microwave pretreatment with citrate buffer pH 6.0) 
were performed. Binding of the first antibody was detected by the avidin-biotin-
peroxidase method and diaminobenzidine peroxidase substrate. Staining was graded 
according to the percentages of stained tumor cells as absent, weak (<30%) or 
strong (>30%). For correlation with other molecular markers, we compared absent 
and weak versus strong staining. 
All tumors were classified according to the WHO classification of tumors of the 
central nervous system (14-15). Essential characteristics including the presence or 
absence of necrosis, pseudopalisading perinecrotic cells, microvascular proliferation, 
giant cells, oligodendroglial-like, sarcomatous, neuronal or other components, and Ki-
67 proliferation index were scored. If the final classification of the tumor was different 
between local and central reference center, the reference diagnosis overruled the 
local diagnosis for data analysis. 
 
Extraction of nucleic acids 
Tumor samples were immediately frozen in liquid nitrogen and stored at –80° C. 
From each patient, a peripheral blood sample was drawn and stored at –80° C. Only 
specimens with an estimated tumor cell content of 80% or more were used for 
molecular analyses. DNA extraction was carried out using DNA blood and tissue 
DNA extraction kits (Qiagen, Hilden, Germany). High molecular weight DNA was 
extracted from peripheral blood leukocytes. 
 
MGMT promoter methylation analysis  
MGMT promoter methylation status was determined by methylation-specific PCR 
(MSP) (16-17), using the following primer sequences to amplify sequences from the 
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methylated or unmethylated MGMT promoter: 5’-
GTTTTTAGAACGTTTTGCGTTTCGAC-3’ and 5’-
CACCGTCCCGAAAAAAAACTCCG-3’ or 5’-
TGTGTTTTTAGAATGTTTTGTGTTTTGAT-3’ and 5’-
CTACCACCATCCCAAAAAAAAACTCCA-3’. A172 glioma cells, obtained from 
American Type Culture Collection, and peripheral blood DNA served as positive and 
negative controls. A further control reaction without template DNA was performed 
together with each PCR experiment. 
 
TP53 mutation analysis 
To amplify TP53 exons 5 to 8, PCR was performed in a volume of 10 µl containing 10 
ng of DNA, 50 mmol/L KCl, 10 mmol/L Tris-HCl, 200 mmol/L of each dNTP, 0.1% 
gelatin, 20 pmol of each primer, 1-2 mmol/L MgCl2, and 0.025 U Taq polymerase. 
The primer sequences are exon 5a 5'-TCAACTCTGTCTCCTTCCTC-3' and 5'-
CTGTGACTGCTTGTAGATGG-3'; exon 5b 5'-GTGGGTTGATTCCACACCCC-3' and 
5'-AACCAGCCCTGTCGTCTCTC-3'; exon 6 5'-AGGCCTCTGATTCCTCACTG-3' 
and 5'-AGAGACCCCAGTTGCAAACC-3'; exon 7 5'-GGCCTCATCTTGGGCCTGTG-
3' and 5'-GTGTGCAGGGTGGCAAGTGG-3'; exon 8 5'-
AATGGGACAGGTAGGACCTG-3' and 5'-ACCGCTTCTTGTCCTGCTTG-3'. The 
PCR conditions on an automated thermal cycler (Biometra, Göttingen, Germany) 
were initially 94°C for 3 min followed by 30 cycles at 94°C/30 sec, 57°C/40 sec and 
extension at 72°C for 40 sec. A final extension step at 72°C for 10 min was added. 
Single strand conformation polymorphism analysis was performed on a sequencing 
apparatus (BlueSeq 400. Serva, Marburg, Germany) using 8% and 14% acrylamide 
gels and electrophoresis at 3 to 6 W for 15 h followed by silver staining of the gels. 
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Aberrantly migrating bands were excised and DNA was extracted. After 
reamplification with the same set of primers the PCR products were sequenced on a 
semiautomated sequencer (ABI 3100, Applied Biosystems, Foster City, CA) using a 
Taq cycle sequencing kit (Applied Biosystems). Each amplicon was sequenced 
bidirectionally. 
 
Determination of EGFR, CDK4, MDM2 and CDKN2A gene dosages 
EGFR amplification was demonstrated by real-time PCR using the ABI PRISM 5700 
sequence detection system (Applied Biosystems, Foster City, CA, USA). The EGFR 
gene dosage was normalized to the dosage of the marker D2S1743 at 2q21.2. The 
following oligonucleotide primers were used: EGFR, 
5’CACTTGCCTCATCTCTCACCATC-3’ and 5’-GACTCACCGTAGCTCCAGAC-3’ 
(110 bp); D2S1743, 5’-CATGACTGCGAGCCCAAGATG-3’ and 5’-
CAGGTGGTGTCATCAGAATCAG-3’ (131 bp). Gene dosages of MDM2, CDK4 and 
CDKN2A were determined by duplex PCR assays, using the following primers: 5’-
GCGATGAATTGATGCTAATGAATG-3’ and 5’-CAGGATCTTCTTCAAATGAATCTG-
3’ for a 99 bp MDM2 amplicon; 5’-GACTGCTACCTTATATCCCTTC-3’ and 5’- 
CTCCCATGTTGGTCACTTAC-3’ for a 102 bp CDK4 amplicon and 5’- 
GAAGAAAGAGGAGGGGCTG-3’ and 5’-GCGCTACCTGATTTCAATTC-3’ for a 338 
bp CDKN2A amplicon. The reference locus was APRT (5’-
CTGGAGCACCTGCTCTCTGC-3’ and 5’-GCCCTGTGGTCACTCATACTGC-3’, 211 
bp amplicon). Positive controls included a glioblastoma with MDM2 and CDK4 
amplification previously demonstrated by Southern blot analysis (18) and the 
glioblastoma cell line U118MG which carries a homozygous CDKN2A deletion. DNA 
extracted from non-neoplastic brain tissue and peripheral blood leukocytes served as 
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constitutional reference. PCR products were separated on 3% agarose gels, and the 
ethidium bromide–stained bands were recorded using the Gel-Doc 1000 system 
(BioRad, Hercules, CA). Quantitative analysis of the signals obtained for the target 
and the reference genes was performed with the Molecular-Analyst software 
(BioRad). Increases in the target (CDK4 and MDM2) to reference gene ratio of more 
than 5-fold of the ratio obtained for the constitutional DNA were considered as gene 
amplification. Decreases in the target (CDKN2A) to reference gene ratio of equal to 
or less than 0.3-fold of the ratio obtained for the constitutional DNA were considered 
as homozygous deletion. 
 
Microsatellite analyses 
The following microsatellite loci were investigated for loss of heterozygosity in each 
tumor: 1p: D1S1608 (1p36.31), D1S548 (1p36.31), D1S1592 (1p36.13), DS1161 
(1p35.2) and D1S1184 (1p31.3); 9p: D9S171 (9p21.3), D9S168 (9p23) and D9S162 
(9p22.1); 10q: D10S541 (10q23.31), D10S209 (10q26.12) and D10S212 (10q26.3); 
19q: D19S433 (19q12), D19S431 (19q12), D19S718 (19q13.2), D19S559 (19q13.32) 
and D19S601 (19q13.41). PCR amplification of these microsatellite markers was 
carried out as reported (19-20). The PCR products were separated by 
electrophoresis on denaturing polyacrylamide gels and visualized by silver staining. 
The allele patterns were assessed for allelic imbalance (9, 20). 
 
IDH-1 mutation analyses 
IDH-1 mutations were assessed as previously described (21). 
 
Statistical analyses 
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Statistical analysis was done using the statistical software R. The Mann-Whitney U, 
Chi-square and Fisher’s exact tests were used to test for association of clinical 
variables and molecular markers. The log-rank test was used to test for survival 
differences among groups. The false discovery rate method (22) was used to adjust 
p-values for multiple testing of correlations between molecular markers and their 
associations with progression-free survival (PFS) and overall survival (OS). PFS was 
calculated from the day of first surgery until tumor progression, death or end of 
follow-up. OS was calculated from the day of first surgery until death or end of follow-
up. The effect of each single molecular marker on PFS and OS was investigated 
using the Cox proportional hazards model adjusting for the major clinical prognostic 
factors age at diagnosis (< 60 versus > 60 years), Karnofsky performance score 
(KPS) (< 80 versus > 80), extent of resection (total versus nontotal), MGMT promoter 
methylation status and adjuvant therapy (radiotherapy alone versus radiotherapy plus 
temozolomide). The multivariate model was applied to all patients who had complete 
information on the five clinical factors named above and who received radiotherapy 
alone or radiotherapy plus temozolomide as their first-line therapy. The models 
presented are calculated without taking interactions terms into account. Variants of 
the multivariate model including interactions between age, MGMT and temozolomide 
were evaluated in a sensitivity analysis, but did not show qualitatively different results 
regarding the prognostic value of the molecular markers. Radiation Therapy 
Oncology Group (RTOG) recursive partitioning analysis (RPA) classes were 
assessed as described (23). 
 
- 11 - 
Results 
 
Clinical parameters 
The study population comprised 291 patients with glioblastoma, 8 with giant cell 
glioblastoma and 2 with gliosarcoma, for a total of 301 patients. The median follow-
up was 29.4 months and 238 patients have died. Clinical patient characteristics are 
summarized in Table 1 (left column). There were no significant differences for any of 
these parameters between male and female patients, except for a trend to younger 
age in male patients (51% versus 39% < 60 years in male and female patients, 
p=0.045). The median ages for patients treated with radiotherapy plus temozolomide 
versus radiotherapy alone were 58.5 (interquartile range, IQR: 48.4-65.4) and 65.4 
(IQR: 56.9-71.1) years. The median KPS for patients treated with radiotherapy plus 
temozolomide versus radiotherapy alone were 90 (IQR: 80-90) and 80 (IQR: 70-
87.5). The median age was 72.1 (IQR: 63.5-76.7) years for patients receiving no 
adjuvant treatment, and their median KPS was 70 (IQR: 62.5-90). 
The median PFS for all patients was 6.8 months (95% CI: 6.2-7.3). The median OS 
was 12.5 months (95% CI: 11.1-14.3). The prognostic relevance of the clinical 
parameters age, KPS and extent of resection is summarized in Table 2, as is the 
prognostic impact of RTOG RPA scores. A significant impact of extent of resection 
became only apparent when patients with a complete resection were compared with 
patients with either subtotal or partial resection or open biopsy pooled. The extent of 
resection was determined by early (<72 h) postoperative MRI or CT (n=199) or 
documented without reference to the imaging modality (n=102). Estimates were 
available for all patients. Tumor localization defined as frontal, temporal, parietal, 
occipital or other was not associated with PFS or OS (data not shown). 
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Kaplan-Meier estimates for PFS and OS by primary treatment are shown in Figure 
1A,B. The PFS data for patients receiving radiotherapy alone (n=64) may be 
overestimated since 30% of these patients had no documented progression prior to 
death whereas this was the case for only 6% of the patients starting on 
temozolomide radiochemotherapy. Hence, follow-up documentation may have been 
less vigorous in patients managed with radiotherapy alone. 
 
Molecular parameters 
Glioblastoma-associated molecular aberrations were observed with the following 
frequencies: TP53 mutation 15%, EGFR amplification 40%, CDK4 amplification 10%, 
MDM2 amplification 6%, CDKN2A homozygous deletion 19%, allelic losses on 
chromosome arms 1p 21%, 9p 41%, 10q 58%, 19q 19%, and 1p+19q 8% (Table 3). 
None of these aberrations was associated with the clinical parameters age, KPS or 
extent of resection (data not shown) or PFS or OS (Fig. 2, Supplementary Table 1). 
This was true for all patients as well as for the subpopulations receiving radiotherapy 
alone, radiotherapy and temozolomide or any of these therapies after correcting for 
multiple testing. Various associations of these molecular parameters were confirmed. 
A complete overview of the pairwise associations between these molecular markers 
and MGMT status is given in Supplementary Table 2. 
MGMT promoter methylation was detected in 44% of the patients and conferred 
superior PFS and OS (Supplementary Table 1). The MGMT status was not 
associated with the clinical parameters age, KPS or extent of resection, nor with the 
first-line treatment administered. Moreover, MGMT promoter methylation status was 
not associated with any of the molecular parameters tested here (Supplementary 
Table 2). MGMT promoter methylation did not translate into a significant prolongation 
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of PFS in patients receiving radiotherapy alone as their first-line treatment. In 
contrast, MGMT promoter methylation was strongly associated with longer PFS and 
OS in patients receiving temozolomide (Fig. 1C,D). We also tested for interactions 
between MGMT promotor methylation and single molecular factors regarding PFS 
and OS, but did not find any relevant interaction (data not shown). IDH-1 mutations 
were found in 16 of 286 patients tested in our data set. They were associated with 
prolonged PFS and OS on univariate analysis (Supplementary Table 1) and 
correlated positively with p53 immunoreactivity, but negatively with EGFR 
amplification and 10q loss (Supplementary Table 2).  
 
Multivariate analyses for outcome 
We established multivariate survival models for PFS and OS including the prognostic 
factors age at diagnosis, KPS, extent of resection, MGMT promoter methylation 
status and adjuvant therapy. These analyses were restricted to the two patient 
populations receiving either radiotherapy alone or radiotherapy plus temozolomide as 
their first-line treatment with full information on all clinical parameters (229 patients, 
Table 1). The models were designed to take each of the factors into account without 
considering interaction terms. 
Independent prognostic factors for PFS were age and MGMT status, and for OS 
were age, KPS, MGMT status and type of adjuvant therapy (Table 4). These 
multivariate models for PFS and OS using age, KPS, extent of resection, MGMT 
status and adjuvant therapy were subsequently used as adjustments for estimating 
the relative risk associated with the effect of single molecular parameters besides 
MGMT. Relative risk estimates and confidence intervals are summarized in 
Supplementary Fig. 1. Among the eleven molecular markers investigated, only IDH-1 
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mutation status was associated with prolonged PFS (RR 0.42, 95%CI 0.19 – 0.91, p= 
0.028) and a trend for improved OS (RR 0.43, 95% CI 0.15 – 1.19, p = 0.10). All 
other markers were not associated with PFS or OS. 
In a sensitivity analysis, we investigated whether more extended multivariate models 
also considering possible two-way interactions between age, MGMT status and 
treatment modality - radiotherapy only or radiotherapy plus temozolomide - would 
impact this conclusion. Although we found some indications for interactions, e.g. of 
age and MGMT status (data not shown), all estimates on the molecular markers 
remained very similar to those shown in Supplementary Fig. 1 with a general 
tendency to shrink towards the relative risk of 1. Hence, the estimates shown are the 
least conservative. 
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Discussion 
 
The German Glioma Network (GGN) aims at generating a data base for the 
diagnosis, treatment and follow-up of glioma patients at several large academic 
centers as well as a tissue bank for translational research. This study focused on the 
prognostic significance of established molecular markers in glioblastoma patients 
enrolled in the first 27 months of funding. The major strengths include the following: 
(i) clinical data were collected prospectively, (ii) patients were enrolled within a short 
time frame, (iii) clinical data were obtained in the temozolomide era which makes 
them particularly relevant for contemporary neuro-oncology, (iv) we studied not only 
overall, but also progression-free survival, and both endpoints stratified by treatment. 
We confirm the major therapy-independent prognostic factors age and KPS. Extent 
of resection was only of prognostic value when completely resected patients were 
compared with all other patients (Table 2) and on univariate analysis only (Table 4). 
In contrast, all molecular aberrations attributed a role in the development of 
glioblastoma, including TP53 mutation, EGFR amplification, CDK4 amplification, 
MDM2 amplification, CDKN2A homozygous deletion, LOH 1p, LOH 9p, LOH 10q, 
LOH 19q or 1p/19q codeletion, were not associated with PFS and OS 
(Supplementary Table 1, Fig. 2). When controlled for age, neither of the parameters 
examined had a prognostic impact in the Boston (TP53, EGFR, CDKN2A, LOH 1p, 
10q, 19q) (2) or Duke (TP53, EGFR, CDKN2A, PTEN) (4) series. An association of 
LOH 10q with poorer survival was identified in the Zurich series (3) whereas EGFR 
amplification was associated with better survival in the Paris series (5) (Table 3). 
As a result of the EORTC NCIC trial (24), temozolomide is now the chemotherapeutic 
agent most commonly used in patients with newly diagnosed glioblastoma (Table 1, 
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Fig. 1A,B). We confirm that MGMT promoter methylation is a strong predictor of 
prolonged progression-free and overall survival in patients receiving temozolomide 
(Fig. 1C,D). Similarly, in a French series, MGMT promoter methylation assumed only 
predictive significance when patients received adjuvant temozolomide (25). 
This study may also have clarified the controversial interrelation of MGMT promoter 
methylation and p53 status. p53 immunoreactivity suggestive of TP53 mutations has 
been linked to low MGMT mRNA expression (26), but did not correlate with MGMT 
promoter methylation (25). We observed that abrogation of wild-type p53 function in 
cultured glioma cells greatly attenuated sensitivity to temozolomide whereas a p53 
mimetic small molecule enhanced temozolomide sensitivity (27). The extensive 
analysis here suggested a trend that patients with TP53 mutations derived more 
benefit from temozolomide chemotherapy than patients with TP53 wild-type tumors, 
but overall no significant association between MGMT promoter methylation and p53 
status became apparent (data not shown). 
Future approaches likely to yield novel predictors of response to therapy and 
outcome include global analyses of gene expression profiling (4, 28) and genomic 
(29) and epigenetic (30) profiling. High throughput analyses have recently resulted in 
the identification of mutations in the active site of the IDH-1 gene as a novel 
prognostic marker in gliomas (21,31-32). The present study supports the hypothesis 
that within the group of primary glioblastomas, IDH-1 mutations are rare and define a 
prognostically favorable subgroup (Fig. 2).  
In summary, we demonstrate here that genetic changes commonly associated with 
the pathogenesis of gliomas do not predict response to therapy in glioblastoma 
patients managed according to current standards of care. MGMT promoter 
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methylation status is clinically the most relevant molecular parameter and should be 
included as a stratification factor in all future trials in glioblastoma. 
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Table 1. Patient characteristics. 
 
  All patients 
(n=301)  
  Patients used  for 
multivariate survival 
modelling (n=229) 
Age at diagnosis (years)         
Median 61.5  60.1  
Range 19.2-86.6  19.2-86.6  
Age classes         
  18-39 ys 27 9%   23 10% 
  40-49 ys 41 14%   33 14% 
  50-59 ys 70 23%   58 25% 
  60-70 ys 92 31%   79 34% 
  70-80 ys 59 20%   33 14% 
  80-90 ys 12 4%   3 1% 
Gender           
  Male 182 60%   144 63% 
  Female 119 40%   85 37% 
KPS           
  90-100 122 (41%)   105 (46%) 
  70-80 128 (43%)   107 (47%) 
  <70 30 (10%)   17 (7%) 
  Missing 21 (7%)   0 (0%) 
Surgery           
  Total resection 136 45%   117 51% 
- 25 - 
  Subtotal resection 108 36%   83 36% 
  Partial resection 27 9%   21 9% 
  Biopsy 27 9%   8 3% 
  No data 3 1%   0 0% 
Review diagnosis           
  Glioblastoma 291 97%   220 96% 
  Gliosarcoma 2 1%   2 1% 
  Giant cell glioblastoma 8 3%   7 3% 
First-line therapy           
  Radiotherapy alone 64 21%   53 23% 
  Radiotherapy plus Temozolomide 189 63%   176 77% 
  Temozolomide alone 10 3%   0 0% 
  Other Chemotherapy alone 2 1%   0 0% 
  Radiotherapy plus other 
chemotherapy 
5 2%   0 0% 
  No therapy 31 10%   0 0% 
RTOG RPA classes     
RPA III 31 10% 27 12% 
RPA IV 102 34% 94 41% 
RPA V 34 11% 27 12% 
RPA VI 6 2% 3 1% 
Missing 128 43% 78 34% 
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Table 2. Clinical parameters, PFS and OS 
 N Median PFS 
(months) 
P Value 
(Logrank 
test) 
Median OS 
(months) 
P Value
(Logrank 
test) 
All patients 301 6.8  12.5  
Age      
  < 60 years 138 9.5 <0.001 19.3 <0.001 
  > 60 years 163 5.8  9.6  
KPS      
  > 80 208 7.2 <0.001 14.9 <0.001 
  < 80 72 5.4  7.6  
Surgery      
  Total resection 136 7.2 0.03 15.0 0.002 
  No total resection 162 6.3  10.2  
RTOG RPA Score      
III 31 10.2 0.006 17.9 <0.001 
IV 102 7.3  18.3  
V 34 6.3  8.7  
VI 6 3.2  5.5  
 
 
Table 3. Comparison of the frequency (%) of molecular genetic alterations in glioblastoma 
 
Reference  Patients
(n)* 
Time of 
diagnosis 
TP53 
mutation 
EGFR 
ampli-
fication 
CDK4 
ampli-
fication 
MDM2 
ampli-
fication 
CDKN2A 
homo-
zygous 
deletion 
LOH 1p LOH 9p LOH 10q LOH 19q PTEN 
mutation 
MGMT 
gene 
promoter 
methy-
lation 
Batchelor 
et al. (2) 
140            1990-
2001 
19 36 Nd nd 33 13 nd 74 24 nd nd
Ohgaki et 
al. (3) 
715            1980-
1994 
31 34 Nd nd 31 nd nd 69 nd 24 nd
Rich et al. 
(4) 
41             Nd 27 41 Nd nd 45 nd nd Nd nd 37 nd
Houillier et 
al. (5) 
220            1997-
2005 
nd 34 7 6 36 19 47 Nd nd nd nd
              
This study 301 2004-
2006 
15           40 10 6 19 21 41 58 19 44
*commonly no full data sets were available for all patients
Table 4. Multivariate analysis of PFS and OS (n=229 patients receiving either 
radiotherapy and temolozomide or radiotherapy alone and data for all factors 
available) 
 
Factor Relative risk of 
progression (95% 
CI) 
P value Relative risk of 
death (95% CI) 
p value 
Age     
< 60 years 1.00  1.00  
> 60 years 1.63 (1.23-2.17) 0.00063 2.19 (1.59-3.01) 1.5*10-6
KPS     
> 80 1.00  1.00  
< 80 1.32 (0.92-1.88) 0.13 1.59 (1.10–2.28) 0.013 
Resection     
No total resection 1.00  1.00  
Total resection 0.91 (0.69-1.20) 0.50 0.76 (0.56-1.03) 0.076 
MGMT promoter     
Unmethylated 1.00  1.00  
Methylated 0.51 (0.38-0.68) 6*10-6 0.39 (0.28-0.54) 1.2*10-8
Adjuvant therapy     
Radiotherapy alone 1.00  1.00  
Radiotherapy plus 
temozolomide 
0.87 (0.63-1.21) 0.41 0.62 (0.43-0.88) 0.0082 
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Supplementary Table 1. Molecular genetic parameters, PFS and OS in all evaluable 
patients (univariate estimates) 
 
  N PFS 
(months) 
P Value* 
(Logrank 
test) 
OS 
(months) 
P Value* 
(Logrank 
test) 
       
TP53 mutation Yes 45 6.0 0.47 9.3 0.46 
 No 247 6.9  12.9  
       
P53 immunoreactivity Negative 169 6.5 0.22 11.7 0.03 
 <30% 
Positive 
63 7.1  13.2  
 >=30% 
Positive 
44 7.1  21.6  
       
EGFR amplification Yes 121 7.1 0.65 13.3 0.98 
 No 174 6.3  11.8  
       
CDK4 amplification Yes 29 7.1 0.86 10.2 0.69 
 No 262 6.7  12.9  
       
MDM2 amplification Yes 19 7.9 0.5 11.6 0.48 
 No 272 6.7  12.7  
       
CDKN2A homozygous 
deletion 
Yes 56 6.6 0.89 10.7 0.35 
 No 234 6.8  13.3  
       
LOH 1p Yes 62 5.4 0.38 12.9 0.63 
 No 217 6.8  12.3  
       
LOH 9p Yes 123 5.5 0.06 10.7 0.06 
 No 145 7.3  13.6  
       
LOH 10q Yes 175 6.3 0.02 11.7 0.006 
 No 80 7.5  17.9  
       
LOH 19q Yes 58 6.5 0.23 14.2 0.08 
 No 221 6.8  11.7  
       
1p/19q codeletion Yes 24 6.7 0.46 17.0 0.2 
 No 257 6.7  12.2  
       
MGMT promoter 
methylation 
Yes 133 7.5 <0.001 18.9 <0.001 
 No 162 6.3  11.1  
       
IDH-1 mutation Yes 16 16.2 <0.001 30.2 0.002 
 No 270 6.5  11.2  
* p values unadjusted for multiple testing
Supplementary Table 2. Correlation of molecular markers (upper right triangle: p-values [Fisher’s exact test]; lower left triangle: 
odds ratios for concurrent presence of markers)  
p-value
Odds ratio 
TP53 
mutation 
p53 
immuno-
reactivity 
EGFR 
amplification
CDK4 
amplification
MDM2 
amplification
CDKN2A 
homozygous 
deletion 
LOH 1p LOH 9p LOH 10q LOH 19q MGMT 
promoter 
methylation 
IDH-1 
mutation 
TP53 mutation            1.3*10-6 + 0.18 0.78 0.33 0.21 0.84 0.87 0.26 0.07 0.74 0.3
p53 Immunoreactivity 6.1+          0.0013+ 1 1 0.79 0.09 0.03 0.24 0.11 0.26 0.005+
EGFR amplfication 0.6 0.4+        0.69 0.33 0.02 0.31 0.01+ 0.004+ 0.37 0.81 0.0003+
CDK4 amplification 1.2 1.0 1.2     2.8*10-12 + 0.002+ 0.05 0.0008+ 0.01+ 0.22 0.05 1 
MDM2 amplification 0.3 0.9 1.7 46+        0.03 0.37 0.036 0.56 0.55 0.81 1 
CDKN2A homozygous 
deletion 
1.6   0.8 2.1 0+ 0  0.009+ 2.2*10-10 + 9.3*10-6 + 0.007+ 0.07 0.7 
LOH 1p       0.8 0.6 1.3 0.3 0.4 2.4+   0.005+ 0.008+ 0.0003+ 0.55 0.2 
LOH 9p 1.1 0.6 1.9+ 0.2+ 0.3 9.6+ 2.4+    6.9*10-7 + 0.22 0.62 0.8 
LOH 10q 1.6 0.7 2.3+ 5.4+ 1.6 8.8+ 2.7+ 4.3+   0.01+ 0.02 0.0006+
LOH 19q       2.0 1.7 0.8 0.4 1.5 2.6+ 3.3+ 1.5 2.9+   0.36 1 
MGMT promoter 
methylation 
1.2          1.3 1.1 0.4 0.9 1.8 1.2 1.2 0.5 1.4  
0.02 
IDH-1 mutation 2.1        4.9+ 0+ 0.6 0.6 0.6 0.2 0.8 0.1+ 1.1 4.0  
+ siginificant at p<0.05 after correction for multiple testing (adjusted p-values not shown); p53 immunoreactivity: >30% versus neg or <30%  
Figure legends 
 
Fig. 1. Clinical course by treatment and MGMT promoter methylation status. 
PFS (A) and OS (B) by primary treatment. 64 patients received radiotherapy alone, 
183 patients radiotherapy plus temozolomide, 17 patients some other treatment, and 
31 patients no adjuvant treatment after surgery. C, D. PFS (C) and OS (D) by MGMT 
promoter methylation status and treatment. 
 
Fig. 2. OS by molecular markers: no significant association with TP53 mutation, 
EGFR amplification, CDK4 amplification, MDM2 amplification, CDKN2A homozygous 
deletion, LOH 1p, LOH 9p, LOH 10q, LOH 19q or 1p/19q codeletion, but major 
prognostic role for IDH-1 mutations. 
 
Supplementary Fig. 1. Forrest plot of hazard ratios for all molecular markers, 
corrected for age (< 60 versus > 60 ys), KPS (> 80 versus < 80), extent of resection 
(total versus other) and chemotherapy containing temozolomide, for PFS (A) and OS 
(B). Only patients treated with radiotherapy alone or radiotherapy plus temozolomide 
were considered. 
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